FindTrial
Sign In

antineoplaston AS2-1

DRUG6 trials

Sponsors

Burzynski Research Institute

Conditions

Adenocarcinoma of the ColonAdenocarcinoma of the ProstateContiguous Stage II Mantle Cell LymphomaIslet Cell CarcinomaMerkel Cell CarcinomaNeuroendocrine CarcinomaNoncontiguous Stage II Mantle Cell LymphomaPituitary Tumor

Phase 2

Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma
WithdrawnNCT00003505
Burzynski Research InstitutePrimary Central Nervous System Lymphoma
Updated: 2013-07-10
Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
WithdrawnNCT00003502
Burzynski Research InstituteContiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma +2
Updated: 2013-07-10
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
WithdrawnNCT00003514
Burzynski Research InstituteIslet Cell Carcinoma, Merkel Cell Carcinoma, Neuroendocrine Carcinoma +1
Updated: 2013-07-10
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
WithdrawnNCT00003517
Burzynski Research InstituteAdenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer +1
Updated: 2013-07-10
Antineoplaston Therapy in Treating Women With Advanced Breast Cancer
WithdrawnNCT00003455
Burzynski Research InstituteRecurrent Breast Cancer, Stage IV Breast Cancer
Updated: 2013-07-10
Antineoplaston Therapy in Treating Patients With Colon Cancer
WithdrawnNCT00003486
Burzynski Research InstituteAdenocarcinoma of the Colon, Recurrent Colon Cancer, Stage IV Colon Cancer
Updated: 2013-07-10